
AZTR
Healthcare · Biotechnology · $3.7M market cap
$0.6084-0.06 (-9.0%)Nov 13, 4:00 PM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · +27.5% over 90 days · 30-day revisions 1 up, 0 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 12, 2026 | After the close | -0.25 | -0.29 | -16.0% |
| Aug 12, 2026 | Time not confirmed | -0.21 | -0.17 | +19.0% |
| May 13, 2026 | Time not confirmed | -0.40 | -2.50 | -525.0% |
| Feb 27, 2026 | After the close | -0.32 | -1.17 | -265.6% |
| Nov 12, 2025 | After the close | -0.77 | -0.67 | +13.0% |
| Aug 11, 2025 | After the close | -1.40 | -1.20 | +14.3% |
| May 14, 2025 | Time not confirmed | — | -0.23 | — |
| Feb 24, 2025 | Before the open | -3.33 | -2.09 | +37.2% |
| Nov 12, 2024 | After the close | -3.20 | -3.30 | -3.1% |
| Aug 12, 2024 | After the close | -21.45 | -18.25 | +14.9% |
| May 9, 2024 | After the close | — | -4.36 | — |
| Mar 15, 2024 | After the close | -35.96 | 27.97 | +177.8% |
| Nov 14, 2023 | After the close | — | -0.16 |
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing…
| — |